Additionally, studies using preclinical models of MASH-induced HCC showed lack of response to anti-PD-1 therapy and, when used prophylactically, led to an increased incidence of HCC associated with an increase in hepatic CD8+PD-1+CXCR6+ T cells.50 This evidence concerns the gene CD8A and hepatocellular carcinoma.